Report on four cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII

CONCLUSION: The number of patients with inhibitory anti-PEG antibodies was significant, and the presence of inhibitors against PEGylated rFVIII emphasizes the importance of individual monitoring when switching FVIII concentrates to ensure safety and efficacy of the treatment.PMID:37543216 | DOI:10.1016/j.jtha.2023.07.019

Source: Thrombosis and Haemostasis - August 5, 2023 Category: Hematology Authors: Andreas Hillarp P ål A Holme Erik P W åland Marie S Le Carola E Henriksson Geir E Tj ønnfjord Ragnhild J M åseide Source Type: research